Role of cytochrome P450 in oxazaphosphorine metabolism: Deactivation via N-dechloroethylation and activation via 4-hydroxylation catalyzed by distinct subsets of rat liver cytochromes P450

Drug Metabolism and Disposition

Volumn 24, Issue 11, 1996, Pages 1254-1262

  Yu, Li ^a   Waxman, David J ^a  

^a USA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; CYTOCHROME P450; DEXAMETHASONE; IFOSFAMIDE; OXAZAPHOSPHORINE DERIVATIVE; PHENOBARBITAL; TROLEANDOMYCIN;

ANIMAL TISSUE; ARTICLE; CATALYSIS; CONTROLLED STUDY; DRUG METABOLISM; ENZYME INACTIVATION; FEMALE; HYDROXYLATION; LIVER MICROSOME METABOLISM; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; BIOTRANSFORMATION; CATALYSIS; CYCLOPHOSPHAMIDE; CYTOCHROME P-450 ENZYME SYSTEM; ENZYME INDUCTION; HYDROXYLATION; IFOSFAMIDE; ISOENZYMES; MALE; MICROSOMES, LIVER; RATS; SUBSTRATE SPECIFICITY;

ANIMALIA; STAPHYLOCOCCUS PHAGE 3A;

EID: 0030476592     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (62)

1. N. E. Sladek: Metabolism of oxazaphosphorines. Pharmacol. Ther. 37, 301-355 (1988).
2. M. J. Moore: Clinical pharmacokinetics of cyclophosphamide. Clin. Pharmacokinet. 20, 194-208 (1991).
3. R. Skinner, I. M. Sharkey, A. D. J. Pearson, and A. W. Craft: Ifosfamide, mesna, and nephrotoxicity in children. J. Clin. Oncol. 11, 173-190 (1993).
4. A. Goldin: Ifosphamide in experimental tumor systems. Semin. Oncol. 9, 14-23 (1982).
5. T. Thigpen: Ifosphamide-induced central nervous system toxicity. Gynecol. Oncol. 42, 191-192 (1991).
6. M. P. Goren, R. K. Wright, C. B. Pratt, and F. E. Pell: Dechloroethylation of ifosfamide and neurotoxicity. Lancet 2, 1219-1220 (1986).
7. A. V. Boddy, Y. Furtun, S. Sardas, O. Sardas, and J. R. Idle: Individual variation in the activation and inactivation of metabolic pathways of cyclophosphamide. J. Natl. Cancer Inst. 84, 1744-1748 (1992).
8. M. J. Lind, H. L. Roberts, N. Thatcher, and J. R. Idle: The effect of route of administration and fractionation of dose on the metabolism of ifosfamide. Cancer Chemother. Pharmacol. 26, 105-111 (1990).
9. K. Norpoth: Studies on the metabolism of isophosphamide (NSC-109724) in man. Cancer Treat. Rep. 60, 437-443 (1976).
10. A. V. Boddy, M. Proctor, D. Simmonds, M. J. Lind, and J. R. Idle: Pharmacokinetics, metabolism and clinical effect of ifosfamide in breast cancer patients. Eur. J. Cancer 31A, 69-76 (1995).
11. D. J. Waxman: Rat hepatic cytochrome P450: comparative study of multiple isozymic forms. In "Cytochrome P450: Structure, Mechanism, and Biochemistry" (P. R. Ortiz de Montellano, ed.), 2nd ed., pp. 525-539. Plenum Press, New York, 1986.
12. F. P. Guengerich: Human cytochrome P450 enzymes. In "Cytochrome P450: Structure, Mechanism, and Biochemistry" (P. R. Ortiz de Montellano, ed.), ed. 2, pp. 473-535. Plenum Press, New York, 1995.
13. S. A. Wrighton and J. C. Stevens: The human hepatic cytochromes P450 involved in drug metabolism. Crit. Rev. Toxicol. 22, 1-21 (1992).
14. F. P. Guengerich: Enzymology of rat liver cytochromes P450. In "Mammalian Cytochromes P450" (F. P. Guengerich, ed.), pp. 1-54. CRC Press, Boca Raton, FL, 1987.
15. T. Shimada, H. Yamazaki, M. Mimura, Y. Inui, and F. P. Guengerich: Interindividual variations in human liver cytochrome P450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J. Pharmacol. Exp. Ther. 270, 414-423 (1994).
16. L. M. Forrester, C. J. Henderson, M. J. Glancey, D. J. Back, B. K. Park, S. E. Ball, N. R. Kitteringham, A. W. McLaren, J. S. Miles, P. Skett, and C. R. Wolf: Relative expression of cytochrome P450 isoenzymes in human liver and association with the metabolism of drugs and xenobiotics. Biochem. J. 281, 359-368 (1992).
17. L. Clarke and D. J. Waxman: Oxidative metabolism of cyclophosphamide: identification of the hepatic monooxygenase catalysts of drug activation. Cancer Res. 49, 2344-2350 (1989).
18. G. F. Weber and D. J. Waxman: Activation of the anti-cancer drug ifosphamide by rat liver microsomal P450 enzymes. Biochem. Pharmacol. 45, 1685-1694 (1993).
19. T. K. H. Chang, G. F. Weber, C. L. Crespi, and D. J. Waxman: Differential activation of cyclophosphamide and ifosphamide by cytochromes P-450 2B and 3A in human liver microsomes. Cancer Res. 53, 5629-5637 (1993).
20. G. A. LeBlanc and D. J. Waxman: Mechanisms of cyclophosphamide action on hepatic P-450 expression. Cancer Res. 50, 5720-5726 (1990).
21. T. K. Chang and D. J. Waxman: Cyclophosphamide modulates rat hepatic cytochrome P450 2C11 and steroid 5α-reductase activity and messenger RNA levels through the combined action of acrolein and phosphoramide mustard. Cancer Res. 53, 2490-2497 (1993).
22. J. A. Ruzicka and P. C. Ruenitz: Cytochrome P-450-mediated N-dechloroethylation of cyclophosphamide and ifosfamide in the rat. Drug Metab. Dispos. 20, 770-772 (1992).
23. C. P. Granvil, T. Wang, G. Batist, and I. W. Wainer: Influence of phenobarbital induction on the enantioselective N-dechloroethylation of ifosfamide enantiomers in the rat. Drug Metab. Dispos. 22, 165-167 (1994).
24. D. J. Waxman and L. Azaroff: Phenobarbital induction of cytochrome P-450 gene expression. Biochem. J. 281, 577-592 (1992).
25. D. J. Waxman: Rat hepatic P450IIA and P450IIC subfamily expression using catalytic, immunochemical, and molecular probes. Methods Enzymol. 206, 249-267 (1991).
26. J. E. Wright, O. Tretyakov, L. J. Ayash, A. Elias, A. Rosowsky, and E. Frei III: Analysis of 4-hydroxycyclophosphamide in human blood. Anal. Biochem. 224, 154-158 (1995).
27. I. Jardine, C. Fenselau, M. Appler, M. N. Kan, R. B. Brundrett, and M. Colvin: Quantitation by gas chromatography-chemical ionization mass spectrometry of cyclophosphamide, phosphoramide mustard, and nornitrogen mustard in the plasma and urine of patients receiving cyclophosphamide therapy. Cancer Res. 38, 408-415 (1978).
28. J. A. Ruzicka and P. C. Ruenitz: Derivatization-liquid chromatographic assay of chloroacetaldehyde in biological samples. J. Chromatogr. 518, 385-389 (1990).
29. G. P. Kaijser, J. H. Beijnen, E. L. Jeunink, A. Bult, H. J. Keizer, J. de Kraker, and W. J. Underberg: Determination of chloroacetaldehyde, a metabolite of oxazaphosphorine cytostatic drugs, in plasma. J. Chromatogr. 614, 253-259 (1993).
30. 31P nuclear magnetic resonance spectroscopy. J. Pharmacol. Exp. Ther. 260, 1133-1144 (1992).
31. D. J. Waxman, D. P. Lapenson, S. S. Park, C. Attisano, and H. V. Gelboin: Monoclonal antibodies inhibitory to rat hepatic cytochromes P-450: cytochrome P-450 form specificities and use as probes for cytochrome P-450-dependent steroid hydroxylations. Mol. Pharmacol. 32, 615-624 (1987).
32. K. O. Cooper, L. M. Reik, Z. Jayyosi, S. Bandiera, M. Kelley, D. E. Ryan, R. Daniel, S. A. McCluskey, W. Levin, and P. E. Thomas: Regulation of two members of the steroid-inducible cytochrome P450 subfamily (3A) in rats. Arch. Biochem. Biophys. 301, 345-354 (1993).
33. J. M. Makowska, G. G. Gibson, and F. W. Bonner: Species differences in ciprofibrate induction of hepatic cytochrome P450 4A1 and peroxisome proliferation. J. Biochem. Toxicol. 7, 183-191 (1992).
34. N. Iwata, K. Suzuki, K. Minegishi, T. Kawanishi, S. Hara, T. Endo, and A. Takahashi: Induction of cytochrome P450 1A2 by musk analogues and other inducing agents in rat liver. Eur. J. Pharmacol. 248, 243-250 (1993).
35. D. J. Waxman and T. K. H. Chang: Hormonal regulation of liver cytochrome P450 enzymes. In "Cytochrome P450: Structure, Mechanism, and Biochemistry" (P. R. Ortiz de Montellano, ed.), 2nd ed., pp. 391-417. Plenum Press, New York, 1995.
36. D. J. Waxman: Rat hepatic cytochrome P-450 isoenzyme 2c: identification as a male-specific, developmentally induced steroid 16α-hydroxylase and comparison to a female-specific cytochrome P-450 isoenzyme. J. Biol. Chem. 259, 15481-15490 (1984).
37. D. Pessayre, M. Konstantinova-Mitcheva, V. Descatoire, B. Cobert, J. C. Wandscheer, R. Level, G. Feldmann, D. Mansuy, and J. P. Benhamou: Hypoactivity of cytochrome P450 after triacetyloleandomycin administration. Biochem. Pharmacol. 30, 559-564 (1981).
38. F. P. Guengerich, W. M. Crawford, Jr., and P. G. Watanabe: Activation of vinyl chloride to covalently bound metabolites: roles of 2-chloroethylene oxide and 2-chloroacetaldehyde. Biochemistry 18, 5177-5182 (1979).
39. D. J. Newton, R. W. Wang, and A. Y. H. Lu: Cytochrome P450 inhibitors: evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metab. Dispos. 23, 154-158 (1995).
40. T. K. H. Chang, F. J. Gonzalez, and D. J. Waxman: Evaluation of triacetyloleandomycin, α-naphthoflavone and diethyldithiocarbamate as selective chemical probes for inhibition of human cytochromes P450. Arch. Biochem. Biophys. 311, 437-442 (1994).
41. D. Walker, J. P. Flinois, S. C. Monkman, C. Beloc, A. V. Boddy, S. Cholerton, A. K. Daly, M. J. Lind, A. D. J. Pearson, P. H. Beaune, and J. R. Idle: Identification of the major human hepatic cytochrome P450 involved in activation and N-dechloroethylation of ifosfamide. Biochem. Pharmacol. 47, 1157-1163 (1994).
42. D. Strotkamp, P. H. Roos, and W. G. Hanstein: A novel CYP3 gene from female rats. Biochim. Biophys. Acta 1260, 341-344 (1995).
43. K. Nagata, F. J. Gonzalez, Y. Yamazoe, and R. Kato: Purification and characterization of four catalytically active testosterone 6β-hydroxylase P-450s from rat liver microsomes: comparison of a novel form with three structurally and functionally related forms. J Biochem. (Tokyo) 107, 718-725 (1990).
44. V. Kurowski and T. Wagner: Comparative pharmacokinetics of ifosfamide, 4-hydroxyifosfamide, chloroacetaldehyde, and 2- and 3-dechloroethylifosfamide in patients on fractionated intravenous ifosfamide therapy. Cancer Chemother. Pharmacol. 33, 36-42 (1993).
45. F. J. Gonzalez: Molecular genetics of the P450 superfamily. Pharmacol. Ther. 45, 1-38 (1990).
46. S. Cholerton, A. K. Daly, and J. R. Idle: The role of individual human cytochromes P450 in drug metabolism and clinical response. Trends Pharmacol. Sci. 13, 434-439 (1992).
47. G. A. LeBlanc, S. S. Sundseth, G. F. Weber, and D. J. Waxman: Platinum anticancer drugs modulate P-450 mRNA levels and differentially alter hepatic drug and steroid hormone metabolism in male and female rats. Cancer Res. 52, 540-547 (1992).
48. M. T. Angley, L. N. Sansom, and I. Stupans: Cyclophosphamide administered repeatedly to the male rat and as a single dose to the female rat: its effects on hepatic and pulmonary P450 and associated enzymes. Xenobiotica 25, 1051-1062 (1995).
49. M. A. Correia: Rat and human liver cytochromes P450: substrate and inhibitor specificities and functional markers. In "Cytochrome P450: Structure, Mechanism, and Biochemistry" (P. R. Ortiz de Montellano, ed.), ed. 2, pp. 607-630. Plenum Press, New York, 1995.
50. F. P. Guengerich and T. Shimada: Oxidation of toxic and carcinogenic chemicals by human cytochrome P-450 enzymes. Chem. Res. Toxicol. 4, 391-407 (1991).
51. J. Y. Jao, W. J. Jusko, and J. L. Cohen: Phenobarbital effects on cyclophosphamide pharmacokinetics in man. Cancer Res. 32, 2761-2764 (1972).
52. S. J. Szefler: Anti-inflammatory drugs in the treatment of allergic disease. Med. Clin. North Am. 76, 953-975 (1992).
53. A. K. Kamada, M. R. Hill, D. N. Ikle, A. M. Brenner, and S. J. Szefler: Efficacy and safety of low-dose troleandomycin therapy in children with severe, steroid-requiring asthma. J. Allergy Clin. Immunol. 91, 873-882 (1993).
54. N. E. Sladek: Therapeutic efficacy of cyclophosphamide as a function of its metabolism. Cancer Res. 32, 535-542 (1972).
55. D. S. Alberts and T. van Daalen Wetters: The effect of phenobarbital on cyclophosphamide antitumor activity. Cancer Res. 36, 2785-2789 (1976).
56. J. H. Hipkens, R. F. Struck, and H. L. Gurtoo: Role of aldehyde dehydrogenase in the metabolism-dependent biological activity of cyclophosphamide. Cancer Res. 41, 3571-3583 (1981).
57. N. E. Sladek: Oxazaphosphorine-specific acquired cellular resistance. In "Drug Resistance in Oncology" (B. A. Teicher, ed.), pp. 375-411. Marcel Dekker, New York, 1993.
58. L. Chen and D. J. Waxman: Intratumoral activation and enhanced chemotherapeutic effect of oxazaphosphorines following cytochrome P450 gene transfer: development of a combined chemotherapy/cancer gene therapy strategy. Cancer Res. 55, 581-589 (1995).
59. L. Chen, D. I. Waxman, D. Chen, and D. W. Kufe: Sensitization of human breast cancer cells to cyclophosphamide and ifosfamide by transfer of a liver cytochrome P450 gene. Cancer Res. 56, 1331-1340 (1996).
60. M. X. Wei, T. Tamiya, M. Chase, E. J. Boviatsis, T. K. H. Chang, N. W. Kowall, F. H. Hochberg, D. J. Waxman, X. O. Breakefield, and E. A. Chiocca: Experimental tumor therapy in mice using the cyclophosphamide-activating cytochrome P450 2B1 gene. Hum. Gene Ther. 5, 969-978 (1994).
61. D. R. Nelson, T. Kamataki, D. J. Waxman, F. P. Guengerich, R. W. Estabrook, R. Feyereisen, F. J. Gonzalez, M. J. Coon, I. C. Gunsalus, O. Gotoh, K. Okuda, and D. W. Nebert: The P450 superfamily: update on new sequences, gene mapping, accession numbers, early trivial names of enzymes, and nomenclature. DNA Cell Biol. 12, 1-51 (1993).
62. D. J. Waxman and C. Walsh: Phenobarbital-induced rat liver cytochrome P450: purification and characterization of two closely related isozymic forms. J. Biol. Chem. 257, 10446-10457 (1982).